that is not involved in binding. As the B1a component is more lethal to nematode, insect and 48 acarid parasites [1] , it is conventional to refer to either the mixture or the B1a component as 49 'ivermectin'. Much attention has been paid to the use of ivermectin against Onchocerca volvulus, 50 a mosquito-transmitted parasitic nematode that causes river blindness, but its use now extends to 51 other human diseases including lymphatic filariasis, strongyloidiasis, scabies and head lice [1] . 52
Despite its broad antiparasitic spectrum, ivermectin is ineffective against platyhelminths [6, 7] , 53 including the blood fluke Schistosoma mansoni which causes bilharzia [8] . 54 55
Ivermectin targets Cys-loop receptors 56
Early investigations into the lethal effect of ivermectin on arthropods and nematodes showed that 57 ivermectin increased chloride conductance in neurons and thus decreased responses of neurons to 58 excitatory input [9, 10] . The search for the identity of this conductance led to the cloning of two 59 novel subunits from the free-living nematode Caenorhabditis elegans that formed a recombinant 60 glutamate-gated chloride channel (GluClR) that was activated irreversibly by nanomolar 61 ivermectin concentrations [2] . Numerous GluClR subunits have since been cloned in various 62 ivermectin-susceptible invertebrates [11, 12] . The identification of GluClRs as the target of 63 ivermectin was confirmed by their high ivermectin sensitivity when expressed recombinantly, 64 their expression in tissues sensitive to low doses of ivermectin, and the development of 65 ivermectin resistance upon their mutation [3, 4, [12] [13] [14] [15] . GluClRs belong to the Cys-loop receptor 66 family of ligand-gated channels, which includes human excitatory nicotinic acetylcholine and 67 type-3 5-hydroxytryptamine receptors (nAChRs and 5-HT 3 Rs) and inhibitory GABA type-A and 68 glycine receptors (GABA A Rs and GlyRs). 69 7
The binding site at the α1 GlyR has also been investigated using mutagenesis and molecular 156 modelling. Ivermectin was modeled as wedging into the same TMD interface, with the 157 benzofuran oriented towards the (+)M2 [50] . Surprisingly, the docking of ivermectin to the 158 Ala288Gly α1 GlyR (this is the M3-Gly position) did not differ greatly from the unmutated 159 receptor, suggesting that the on-rate of ivermectin, rather than the ultimate binding conformation 160 of ivermectin, is changed by this substitution [50] . Alternately, the glycine substitution may 161 increase the gating equilibrium constant, thus facilitating receptor activation by ivermectin. Bulky 162 substitutions at only two positions decreased both agonist and modulatory effects of ivermectin, 163
indicative of a decisive role in binding. These positions are (+)Ala288 and (-)Pro230. Both of 164 these positions are highlighted in red in Figure 3c , revealing the apparent requirement of a small 165 residue at the M3-Gly position and the conservation of the "M1-Pro". M1-Pro is in close 166 proximity to the crucial benzofuran moiety of ivermectin (Figure 3b ), providing a possible steric 167 explanation for decreased binding at this mutant. In addition, this highly conserved residue 168 disrupts M1 helical structure thereby exposing a backbone carbonyl that is thought to form a H-169 bond with the ivermectin C7-OH [44] . However, the existence of this bond requires confirmation, 170
given that C7-OH is equidistant from both the M1 backbone carbonyl and the endogenous 171 ivermectin C1 carbonyl. 172 A significant role for the third putative H-bond (between O14 and T285 -see Figure 3b ) can be 173 eliminated on the basis of site-directed mutagenesis experiments in the Ala288Gly α1 GlyR, and 174 the fact that the three GluClRs with nanomolar ivermectin affinity do not contain H-bonding 175 sidechains at the corresponding M3 position [50] . Moving deeper into the pore, substitution of α1 176 GlyR (+)M3-Leu291, (+)M2-Thr264 or (-)M1-Leu233 for bulky Trp sidechains does not reduce 177 ivermectin sensitivity but converts ivermectin from an agonist to an antagonist of glycine-178 activated currents [50] . Still further removed from the binding site, mutations in the conserved 179
Cys-loop, the pre-M1 domain and the M2-M3 linker (Figure 1b ) decrease ivermectin potency 180 most likely by impairing its gating efficacy [14, 18, [49] [50] [51] . 181 Native Cys-loop receptors are often heteromeric and thus do not necessarily possess the five 182 binding sites available to ivermectin in homomers. The following evidence at the GlyR, however, 183 suggests that the binding of two molecules of ivermectin is sufficient for either direct activation 184 8 or potentiation. First, ivermectin activates α1β heteromeric and α1 homomeric GlyRs with equal 185 potency [21] , even though heteromers possess a β-α1-β-α1-β arrangement [52] and ivermectin 186 only binds to the (+)α1/(-)β interface [48] . Second, the β-Ile312Gly substitution (at the M3-Gly 187 position) confers sensitivity to potentiation on the otherwise ivermectin-insensitive α1-188 Ala288Phe/β heteromer, presumably by introducing a (+)β/(-)α1 ivermectin binding site [48] . 189
190

M2 H-bonds 191
The putative H-bond between the ivermectin C5-OH and the M2- Ser-Asp/(-)Gln-Gln, (+)Thr-Ala-Asn/(-)Gln-Gln, (+)Thr-Ala-Asn/(-)Gln-Gln and (+)Ala-Thr-216
Asn/(-)Gln-Gln arrangements, and thus present an overwhelmingly polar environment to the 217 ivermectin C5-OH moiety. Given that the α1 GlyR possesses a similar polarity in this region to 218
GluClRs, we infer that its large M3-Gly sidechain is solely responsible for its reduced ivermectin 219 sensitivity. UNC-49B/UNC-49C heteromeric GABA A Rs possess an M3-Gly at the (+) faces of 220 UNC-49C, yet are not activated by ivermectin [54, 55] . However, with a (+)Thr-Met-Asn/(-)Gln-221
Leu arrangement, they are distinct from the GluClRs and GlyRs in that both the M2-14' and M2-222 functional homomeric β GluClRs from C. elegans and C. onchophora are also completely 233 insensitive to ivermectin [59] , and studies with radiolabelled ivermectin show that it does not 234 even bind to the H. contortus β GluClR [60] . These receptors contain a (+)Thr-Gln-Asn/(-)Gln-235
Met arrangement and an M3-Gly. We thus conclude that the (-)M1-Met is responsible for 236 disrupting ivermectin sensitivity. In the above analysis, we have used the GluClR crystal 237 structure to infer that the five polar residues are essential for high ivermectin affinity. However, it 238 is also possible that the overwhelmingly polar environment facilitates receptor gating by 239 ivermectin. 240
An alternate possibility in GABA A Rs is that ivermectin binds to a different site. For example, 241 GAB-1/HG1A heteromers and UNC-49B homomers possess Val, Leu or Asn residues at the M3-242
Gly position, and these receptors are potentiated but not activated by ivermectin [54, 55, 61] , 243 perhaps reflecting the exclusion of ivermectin from the interfacial site and the existence of an 244 alternate site. Moreover, HG1A and HG1E differ by only four amino acids -in the ECD and in 245 M4 -and, whereas GAB1/HG1A heteromers are potentiated by ivermectin, GAB1/HG1E 246 heteromers are inhibited [61] . An alternative site, consistent with HG1A/E structural differences, 247 might be similar to that proposed for the mammalian α7 nAChR (see below). The possibility of 248 distinct ivermectin binding sites in various GABA A Rs, together with the large diversity in 249 GABA A R subunits, might underlie the differential effects of ivermectin on various native 250 GABA A R preparations [62] . 251 252
An alternative site for potentiation of nAChRs 253
Due to the differing M2-M3 domain lengths in anionic and cationic Cys-loop receptors, it is 254 difficult to determine which amino acid occupies the M3-Gly position in the mammalian α7 255 nAChR [63] . Most alignments suggest that Ala275 in the α7 nAChR and Leu279 in the Torpedo 256 marmorata (marbled electric ray) nAChR α subunit occupy the M3-Gly position. Although the 4 257 Å resolution structure of the T. marmorata nAChR places this Leu279 in the (+)M3 helix, it faces 258 the outside of the membrane, 1-2 helical turns above the level of (-)M1Pro (Figure 5a ). In the T. 259 marmorata nAChR structure, the (+)M3 residue physically opposite (-)M1-Pro is either Met282, 260
Ile283 or Ile286, which equate with little ambiguity to Met278, Ile279 and Gly282 in the α7 261 nAChR (Figure 5a,b) . Thus, the α7 nAchR structural equivalent to the M3-Gly might Gly282, 262 and the selectivity of ivermectin for α7 nAChRs over insensitive cationic Cys-loop receptors may 263 be due to Val, Ile and Thr sidechains at this position (e.g., in nematode ACR-16 receptors and 264 mammalian 5-HT 3 Rs [64, 65] ). Accordingly, the lack of H-bond propensity at M2-14', M2-15' and 265 M2-19' positions in the α7 nAChR might limit the direct agonist efficacy of ivermectin. 266
However, if the structural equivalent in α7 nAChR is Met278 or Ile279, access of ivermectin to 267 the interfacial site is likely precluded, and ivermectin might bind to a distinct site. 268
Computer docking simulations from two separate laboratories have shown that the lowest energy 269 docking of ivermectin to the α7 nAChR was in an intrasubunit cavity, as opposed to the 270 interfacial site in anionic receptors [64, 66] bond in the spiroketal of abamectin is the only difference from ivermectin.) It is also possible that 290 ivermectin insensitivity may be caused by mutations that allosterically disrupt the efficacy with 291 which ivermectin activates the receptors, without necessarily affecting ivermectin affinity. This 292 was first suggested by an M2-M3 linker mutation in a Drosophila GluClR that caused a four-fold 293 increase in ivermectin LD 100 [14] . Disruptions to the efficacy of GluClR gating by ivermectin 294 most likely account for the effects of mutations identified in several resistant H. contortus strains 295 [18, 49] . Of course, if a GluClR mutation converts ivermectin to an inhibitor, as demonstrated at 296 recombinant GlyRs and nAChRs (above), the usual CNS depression elicited by ivermectin could 297 be converted to excitation. This may underlie the resistance seen in nematodes with an up-298 regulation of HG1E GABA A R subunits that are inhibited by ivermectin [61, 68] . 299 300
Predicting species susceptibility to ivermectin 301
The discovery of molecular determinants of ivermectin sensitivity in Cys-loop receptors provides 302 an opportunity to investigate parasites of known ivermectin susceptibility to establish the 303 molecular basis for this susceptibility. The complete genome of the trematode S. mansoni reveals 304 13 Cys-loop receptor subunits [70] , much fewer than the 102 found in C. elegans and 45 in 305 humans [16, 17] . It is therefore likely that ivermectin has fewer potential Cys-loop receptor targets 306 in S. mansoni than in C .elegans which might help explain why S. mansoni is insensitive to 307 ivermectin. On the other hand, arthropods also possess few GluClRs but are ivermectin-308 susceptible, suggesting that there must be some feature of S. mansoni GluClRs (other than a small 309 number in the genome) that renders them insensitive to ivermectin. 
Concluding remarks 329
Ivermectin binds to nematode GluClRs and mammalian GlyRs at the interface of adjacent (+) and 330 (-) subunits in the TMD of the receptor. High affinity for this site is controlled by an M3 Gly 331 residue on the (+)M3 helix that allows rapid access to the site. The C5 hydroxyl of the ivermectin 332 benzofuran likely forms an H-bond within the subunit interface cleft, leading to potent channel 333 activation. Potent activity requires polar sidechains at either M2-14', M2-15' or M2-19' (and 334 perhaps other) positions. Scanning Cys-loop receptor amino acid sequences for these 335 determinants predicts ivermectin sensitivity reasonably well, and scanning genomes for these 336 transcripts may enable the prediction of species susceptibility to ivermectin. However, several 337
questions are yet to be answered, including the structural basis for modulation (not activation) by 338 ivermectin of certain GABA A Rs and nAChRs, and the inability of ivermectin to activate β 339
GluClRs. Attempts to answer these questions will be aided by the structural template provided by 340 the GluClR crystal structure. Given the emergence of ivermectin resistance in parasitic nematode 341 pests [75, 76] are structurally more equivalent to GluClR M3-Gly, indicated by the proximity to M1-Pro (red in 401 both receptors). Shown in magenta are several residues that line a space between M1 and M4 of 402 each subunit (these are equivalent in amino acid alignments but were selected simply due to their 403 apparent structural equivalence). Shown in cyan are residues equivalent to those whose 404 substitution in the rat α7 nAChR decreases potentiation by ivermectin [64] ; only one of these is 405 16 indicated in the GluClR structure, as it is one of the aligned residues in 
